γδ T cells, including Vδ1 and Vδ2 T cells, can recognize tumor-associated ligands neglected by conventional αβ T cells in a MHC -independent manner. Little is known regarding the anticancer potential and the possibility to isolate and expand Vd1 T cells to therapeutically relevant numbers. In this study, we have detected low frequencies of Vδ1 T cells among tumor-infiltrating lymphocyte (TIL) products for adoptive cell transfer generated from melanoma metastases. An increased frequency of Vδ1 T cells was found among the cell products from patients with an advanced disease stage. Vδ1 T cells displayed in vitro antitumor activities and sufficient proliferative potential to generate over 1 × 109 cells using current protocols for T cell transfer. Infusion of Vδ1 T cells together with high numbers of αβ TILs in a clinical trial was safe and well tolerated. These data suggest that Vδ1 T cells should be further scrutinized as a potentially useful tool for the treatment of patients with metastatic melanoma. © 2012 Landes Bioscience.
CITATION STYLE
Donia, M., Ellebaek, E., Andersen, M. H., Straten, P. T., & Svane, I. M. (2012). Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology, 1(8), 1297–1304. https://doi.org/10.4161/onci.21659
Mendeley helps you to discover research relevant for your work.